Education
About Us
Working with TipRanks
Follow Us
Baxter International (BAX)
NYSE:BAX
BAX Stock Chart & Stats
$16.61
$0.05(0.17%)
At close: 4:00 PM EST
$16.61
$0.05(0.17%)
Day’s Range― - ―
52-Week Range$16.08 - $34.52
Previous CloseN/A
Volume899.70K
Average Volume (3M)11.00M
Market Cap
$8.31B
Enterprise Value$16.36B
Total Cash (Recent Filing)$1.97B
Total Debt (Recent Filing)$9.78B
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Apr 30, 2026EPS Estimate
0.32Next Dividend Ex-DateN/A
Dividend Yield2.75%
Share Statistics
EPS (TTM)0.36
Shares Outstanding514,490,050
10 Day Avg. Volume10,910,253
30 Day Avg. Volume11,001,788
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)1.60
Price to Sales (P/S)0.87
P/FCF Ratio30.35
Enterprise Value/Market Cap1.97
Enterprise Value/Revenue1.45
Enterprise Value/Gross Profit4.84
Enterprise Value/Ebitda21.36
Forecast
1Y Price Target
$20.27Price Target Upside22.03% Upside
Rating ConsensusHold
Number of Analyst Covering12
EPS Forecast (FY)1.93
Revenue Forecast (FY)$11.35B
Bulls Say, Bears Say
Bulls Say
Operational Improvement In Core BusinessesAnalyst believes operational gains in Advanced Surgery, Care & Connectivity Solutions and Drug Compounding under CEO Andrew Hider's transformation initiative can drive stronger growth and improved profitability over time.
Revenue OutperformanceAnalyst notes revenue exceeded expectations across all business segments, with international strength indicating broad demand resilience and supporting upside to top-line momentum.
Valuation Gap Versus PeersAnalyst highlights the stock trades at a notable discount to peer averages, suggesting potential upside if execution and margin recovery materialize.
Bears Say
Credit Outlook And Cash Flow ConcernsS&P moved the credit outlook to Negative and flagged free cash flow generation and an adjusted leverage measure that includes leases and pension shortfalls as key factors that could pressure the credit profile if cash flow underperforms.
Product Disruption And Execution RiskAnalyst points to a ship hold and related uncertainty for the Novum IQ infusion pump program that reduced shipments and left customers awaiting clarity on corrections, creating near-term revenue and execution risk.
Profitability And Margin PressureAnalyst reports earnings were pressured by an unfavorable product mix, inventory adjustments and a higher tax rate, causing gross and operating margins to trail market expectations.
Baxter International News
BAX FAQ
What was Baxter International’s price range in the past 12 months?
Baxter International lowest stock price was $16.08 and its highest was $34.52 in the past 12 months.
What is Baxter International’s market cap?
Baxter International’s market cap is $8.31B.
When is Baxter International’s upcoming earnings report date?
Baxter International’s upcoming earnings report date is Apr 30, 2026 which is in 37 days.
How were Baxter International’s earnings last quarter?
Baxter International released its earnings results on Feb 12, 2026. The company reported $0.36 earnings per share for the quarter, missing the consensus estimate of $0.536 by -$0.176.
Is Baxter International overvalued?
According to Wall Street analysts Baxter International’s price is currently Undervalued.
Does Baxter International pay dividends?
Baxter International pays a Quarterly dividend of $0.01 which represents an annual dividend yield of 2.75%. See more information on Baxter International dividends here
What is Baxter International’s EPS estimate?
Baxter International’s EPS estimate is 0.32.
How many shares outstanding does Baxter International have?
Baxter International has 514,490,050 shares outstanding.
What happened to Baxter International’s price movement after its last earnings report?
Baxter International reported an EPS of $0.36 in its last earnings report, missing expectations of $0.536. Following the earnings report the stock price went down -15.989%.
Which hedge fund is a major shareholder of Baxter International?
Currently, no hedge funds are holding shares in BAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Baxter International Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$20.27 (22.03% Upside)
$20.27 (22.03% Upside)
Blogger Sentiment
Bullish
BAX Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 15.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.1%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.04%
12-Months-Change
Fundamentals
Return on Equity
-13.78%
Trailing 12-Months
Asset Growth
-22.21%
Trailing 12-Months
Company Description
Baxter International
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
BAX Company Deck
BAX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: solid top-line growth in Q4 (+8% reported; +3% operational) and notable strength in Advanced Surgery, CCS capital orders (nearly +30%), Drug Compounding (+18%), and improved cash generation. However, material margin deterioration (gross margin down ~900 bps), an adjusted EPS miss, ongoing Novum pump disruptions and IV Solutions demand rebaselining, tariff headwinds ($130–$140M), and Pharmaceutical weakness are significant challenges. Management outlined concrete organizational and operational actions (new operating model, Baxter GPS, cost structure work) and provided a cautious, back-half-weighted 2026 outlook (flat organic growth, 13%–14% operating margin, $1.85–$2.05 EPS) while emphasizing deleveraging and continuous improvement. Overall, the positives are meaningful but are offset by substantial margin and execution risks, with improvement expected to be gradual into the back half of 2026.View all BAX earnings summariesBAX Net sales Breakdown
47.13% Medical Products and Therapies
27.31% Healthcare Systems and Technologies
22.17% Pharmaceuticals
3.39% Other
BAX Stock 12 Month Forecast
Average Price Target
$20.27
▲(22.03% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---